Stockscreener 앱 받기
0.9257
4.12%
0.0366
전일 마감가:
$0.8891
열려 있는:
$0.87
하루 거래량:
86,433
Relative Volume:
0.01
시가총액:
$21.38M
수익:
-
순이익/손실:
$-16.28M
주가수익비율:
-0.0665
EPS:
-13.91
순현금흐름:
$-13.75M
1주 성능:
-0.60%
1개월 성능:
-18.80%
6개월 성능:
+32.11%
1년 성능:
-62.22%
1일 변동 폭
$0.8584
$0.9257
1주일 범위
$0.85
$0.94
52주 변동 폭
$0.281
$3.85
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
명칭
Pasithea Therapeutics Corp
전화
(702) 514-4174
주소
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
KTTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.9257 | 20.53M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Aug Big Picture: Is Finward Bancorp benefiting from interest rate changes2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Pasithea Therapeutics regains Nasdaq compliance - MSN
New Highs: Can Pasithea Therapeutics Corp grow without external fundingJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - baoquankhu1.vn
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway - TipRanks
Pasithea provides updates on clinical trials for MEK inhibitor drug By Investing.com - Investing.com Nigeria
Pasithea provides updates on clinical trials for MEK inhibitor drug - Investing.com
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - Investing News Network
Pasithea Therapeutics Updates Clinical Trial Timelines for PAS-004 in Neurofibromatosis and Advanced Cancer - Quiver Quantitative
Risk Hedge: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising ratesMarket Growth Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pasithea Therapeutics (NASDAQ:KTTA) Stock Rating Upgraded by Wall Street Zen - Defense World
How Pasithea Therapeutics Corp. Equity Warrant stock reacts to oil pricesJuly 2025 EndofMonth & Stepwise Trade Execution Plans - ulpravda.ru
How analysts rate Pasithea Therapeutics Corp. stock today2025 Trade Ideas & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Why hedge funds are buying Pasithea Therapeutics Corp. stock2025 Momentum Check & Verified Swing Trading Watchlists - ulpravda.ru
What is the fair value of Pasithea Therapeutics Corp. Equity Warrant stock now2025 Bull vs Bear & Daily Growth Stock Tips - Улправда
Why Pasithea Therapeutics Corp. stock remains undervaluedJuly 2025 Selloffs & Daily Entry Point Trade Alerts - Улправда
How Pasithea Therapeutics Corp. stock benefits from strong dollar2025 Risk Factors & Short-Term High Return Ideas - Улправда
How Pasithea Therapeutics Corp. stock compares to industry benchmarks2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - Улправда
Why Did KTTA Stock Soar A Whopping 48% Today? - MSN
Is Pasithea Therapeutics Corp. Equity Warrant stock a dividend growth opportunity2026 world cup usa national team quarterfinals star players transition play group prediction analysis - ulpravda.ru
Will Pasithea Therapeutics Corp. Equity Warrant stock deliver shareholder value2026 world cup usa national team quarterfinals young talents transition play knockout prediction tactical review - ulpravda.ru
Pasithea Therapeutics Corp Stock Analysis and ForecastMomentum Trading Signals & Big Profit Low Capital - earlytimes.in
Is Pasithea Therapeutics Corp. overvalued or undervalued? - MarketsMojo
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Can Pasithea Therapeutics Corp. stock hit analyst price targetsWeekly Stock Analysis & Safe Entry Momentum Stock Tips - Улправда
What sentiment indicators say about Pasithea Therapeutics Corp. Equity Warrant stockJuly 2025 Pullbacks & Reliable Entry Point Trade Alerts - Улправда
Is Pasithea Therapeutics Corp. Equity Warrant stock cheap at current valuationTrade Volume Summary & Weekly Sector Rotation Insights - Улправда
Will Pasithea Therapeutics Corp. stock return to pre crisis levelsWeekly Investment Report & Fast Gaining Stock Strategy Reports - Улправда
What hedge fund activity signals for Pasithea Therapeutics Corp. Equity Warrant stockLong Setup & Accurate Entry and Exit Point Alerts - Улправда
Recap Report: What sentiment indicators say about Pasithea Therapeutics Corp. Equity Warrant stockTrade Analysis Report & Daily Oversold Stock Bounce Ideas - Улправда
Pasithea Therapeutics Regains Nasdaq Compliance - The Globe and Mail
Pasithea Therapeutics regains Nasdaq compliance with minimum bid price rule - Investing.com
Pasithea Therapeutics (NASDAQ: KTTA) back in Nasdaq bid price compliance - Stock Titan
Market Review: Is Pasithea Therapeutics Corp stock a contrarian buy2025 Top Gainers & Safe Capital Allocation Plans - moha.gov.vn
LEAHY EMER Insider Trades - Nasdaq
SCHNEIDERMAN DANIEL H Insider Trades - Nasdaq
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Pasithea Therapeutics Corp - GuruFocus
Pasithea Therapeutics (NASDAQ:KTTA) Upgraded at Zacks Research - Defense World
What is HC Wainwright’s Forecast for KTTA FY2025 Earnings? - Defense World
HC Wainwright Begins Coverage on Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
There is no way Pasithea Therapeutics Corp (KTTA) can keep these numbers up - setenews.com
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of Pasithea Therapeutics (KTTA) with Buy Recommendation - Nasdaq
Pasithea Therapeutics stock initiated with Buy rating at H.C. Wainwright - Investing.com
HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target - marketscreener.com
Pasithea Therapeutics Corp (KTTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pasithea Therapeutics Corp 주식 (KTTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
4.73%
0.92%
자본화:
|
볼륨(24시간):